Press release
Sarepta Therapeutics Announces First Quarter 2025 Financial Results and Recent Corporate Developments
Net product revenues for the first quarter 2025 totaled $611.5 million, a 70% increase over the same quarter of the prior year ELEVIDYS net product revenue
About this update from Sarepta Therapeutics, Inc.
[{"type":"text","content":"\n\nNet product revenues for the first quarter 2025 totaled $611.5 million, a 70% increase over the same quarter of the prior year\n\n\nELEVIDYS net product revenue for the first quarter totaled $375.0 million; Royalty revenue from the sales of ELEVIDYS by Roche for the quarter totaled $4.0 million\n\n\nRevised 2025 total net product revenues guidance to $2.3 to $2.6 billion\n\n\nMeaningfully advanced multiple clinical candidates in limb-girdle muscular dystrophy portfolio\n\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nSarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 2025.\n\n“In the first quarter, we achieved net product revenue of $611.5 million, a 70% increase over the same quarter prior year; our PMO franchise performed well at $236.5 million; and ELEVIDYS achieved $375.0 million, growing at 180% over the same quarter prior year. However, we also faced headwinds in the quarter. While we are taking a variety of actions to address and resolve these challenges, we have adjusted our guidance for 2025 to $2.3 billion to $2.6 billion,” said Doug Ingram, president and chief executive officer, Sarepta Therapeutics. “The broader biotech market has also faced significant pressure in the first quarter of 2025. Fortunately, as an organization with four life-changing therapies, significant revenue, and a deep pipeline, Sarepta is well-positioned to navigate these chaotic times. To that end, in addition to driving the launch of ELEVIDYS and the continued performance of our three approved PMO therapies, we continue to invest in our pipeline and look forward to a significant number of LGMD gene therapy approvals in the coming few years. We are also advancing our siRNA platform and look forward to proof of concept and proof of biology readouts later this year in both our DM1 and FSHD1 programs.”\n\nCorporate Highlights:\n\n\nIn the first quarter Sarepta closed its global licensing and collaboration agreement with Arrowhead Pharmaceuticals, Inc. (“Arrowhead”). The agreement includes global rights to four clinical-stage and three preclinical-stage programs in muscle, central nervous system, and rare pulmonary disorders, including potential best-in-class siRNA-based treatments for DM1 and FSHD1. The agreement adds meaningfully to Sarepta’s mi...